PAROXYSMAL HEMOGLOBINURIA

Clinical trials for PAROXYSMAL HEMOGLOBINURIA explained in plain language.

Never miss a new study

Get alerted when new PAROXYSMAL HEMOGLOBINURIA trials appear

Sign up with your email to follow new studies for PAROXYSMAL HEMOGLOBINURIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug pegcetacoplan tested in teens with rare blood disorder

Disease control Recruiting now

This study tests a drug called pegcetacoplan in 12 to 17-year-olds with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The drug aims to control the disease by blocking part of the immune system. The trial will check safety, how the…

Matched conditions: PAROXYSMAL HEMOGLOBINURIA

Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 28, 2026 00:00 UTC

PAROXYSMAL HEMOGLOBINURIA

Get alerted when new PAROXYSMAL HEMOGLOBINURIA trials appear

New drug pegcetacoplan tested in teens with rare blood disorder